Genome-wide CRISPR-Cas9 screens identify mechanisms of BET bromodomain inhibitor sensitivity
Open Access
- 21 October 2021
- Vol. 24 (11) , 103323
Abstract
No abstract availableKeywords
Funding Information
- Novartis AG
This publication has 89 references indexed in Scilit:
- Epigenetic and genetic features of 24 colon cancer cell linesOncogenesis, 2013
- AKT induces senescence in human cells via mTORC1 and p53 in the absence of DNA damage: implications for targeting mTOR during malignancyOncogene, 2011
- BET Bromodomain Inhibition as a Therapeutic Strategy to Target c-MycCell, 2011
- Novel high-throughput assay to assess cellular manganese levels in a striatal cell line model of Huntington's disease confirms a deficit in manganese accumulationNeuroToxicology, 2011
- Phase I clinical trial of hepatic arterial infusion of paclitaxel in patients with advanced cancer and dominant liver involvementCancer Chemotherapy and Pharmacology, 2010
- Selective inhibition of BET bromodomainsNature, 2010
- Ragulator-Rag Complex Targets mTORC1 to the Lysosomal Surface and Is Necessary for Its Activation by Amino AcidsCell, 2010
- How I treat paroxysmal nocturnal hemoglobinuriaBlood, 2009
- Ultrafast and memory-efficient alignment of short DNA sequences to the human genomeGenome Biology, 2009
- A probability-based approach for the analysis of large-scale RNAi screensNature Methods, 2007